Insider and congress filings
Regeneron Pharmaceuticals, Inc. (REGN)
About Regeneron Pharmaceuticals, Inc.
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Leonard S. Schleifer
- Employees
- 15,410
- Listed since
- Apr 2, 1991
- Market value
- $83.2B
- Price to earnings
- 19.3
- Earnings per share
- $41.86
- Dividend yield
- 0.46%
Earnings
6 reported quarters · next on Oct 28, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Jul 30, 2026 | $14.29 | $10.16 | $4.3B | $3.8B | EPS beatRevenue beat |
| Q1 FY2026reported Apr 29, 2026 | $9.47 | $8.91 | $3.6B | $3.5B | EPS beatRevenue beat |
| Q4 FY2025reported Jan 30, 2026 | $11.44 | $10.74 | $3.9B | $3.8B | EPS beatRevenue beat |
| Q3 FY2025reported Oct 28, 2025 | $11.83 | $9.65 | $3.8B | $3.6B | EPS beatRevenue beat |
| Q2 FY2025reported Aug 1, 2025 | $12.89 | $8.43 | $3.7B | $3.3B | EPS beatRevenue beat |
| Q1 FY2025reported Apr 29, 2025 | $8.22 | $8.62 | $3.0B | $3.2B | EPS missRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 24, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Daniel P. Van PlewExecutive Vice President and General Manager, Industri | $983K | $2.7M | $5.1M | $8.8M |
| Andrew J. Murphy, Ph.D.Executive Vice President, Co-Chief Scientific Officer | $820K | $2.7M | $5.0M | $8.5M |
| Joseph J. LaRosaExecutive Vice President, General Counsel and Secretar | $916K | $1.8M | $4.7M | $7.5M |
| Leonard S. SchleiferM.D., Ph.D. Board co-Chair, President and Chief Execut | $2.0M | $0 | $5.3M | $7.3M |
| Christopher FenimoreExecutive Vice President, Finance and Chief Financial | $725K | $2.2M | $4.1M | $7.0M |
| George D. YancopoulosM.D., Ph.D. Board co-Chair, President and Chief Scient | $2.0M | $0 | $5.0M | $6.9M |
The summary compensation table from the 2025 proxy statement, current executives only. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| Blackrock, Inc. | $5.7B | 9,113,506 | +1.9% | 8.81% |
| Vanguard Capital Management LLC | $4.1B | 6,629,759 | -0.4% | 6.41% |
| Dodge & Cox | $3.0B | 4,871,137 | +9.3% | 4.71% |
| State Street Corp | $3.0B | 4,834,688 | +3.6% | 4.68% |
| Invesco Ltd. | $2.5B | 3,940,665 | +80.7% | 3.81% |
| Jpmorgan Chase & Co | $2.4B | 3,774,199 | -12.5% | 3.65% |
| Vanguard Portfolio Management LLC | $2.0B | 3,175,313 | +84.5% | 3.07% |
| Franklin Resources Inc | $1.7B | 2,771,839 | +1.8% | 2.68% |
| Geode Capital Management, LLC | $1.6B | 2,625,810 | +0.7% | 2.54% |
| Nuveen, LLC | $1.3B | 2,019,974 | -2.2% | 1.95% |
| Loomis Sayles & Co L P | $1.2B | 1,859,172 | -2.8% | 1.80% |
| Price T Rowe Associates Inc | $953.8M | 1,529,709 | -29.8% | 1.48% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Open-market insider trades
13 filings of 296 on record| Insider | Action | Shares | Price | Value | Trade date | Delay |
|---|---|---|---|---|---|---|
| Marion McCourtEVP Commercial | Sold | 1,215 | $850.00 | $1.0M | Sep 2, 2026 | 1d |
| Kathryn GuariniDirector | Sold | 400 | $850.00 | $340K | Sep 2, 2026 | 1d |
| Marion McCourtEVP Commercial | Sold | 1,131 | $857.39 | $970K | Sep 3, 2026 | 0d |
| Huda Y. ZoghbiDirector | Sold | 800 | $800.00 | $640K | Aug 10, 2026 | 2d |
| Kathryn GuariniDirector | Sold | 400 | $800.00 | $320K | Aug 10, 2026 | 2d |
| Arthur F. RyanDirector | Sold | 200 | $650.15 | $130K | Jul 2, 2026 | 5d |
| Arthur F. RyanDirector | Sold · 9 lines | 78 | $704.79 | $55K | May 1, 2026 | 3d |
| Arthur F. RyanDirector | Sold · 8 lines | 92 | $777.51 | $72K | Apr 1, 2026 | 2d |
| Arthur F. RyanDirector | Sold · 8 lines | 67 | $784.41 | $53K | Mar 2, 2026 | 1d |
| Huda Y. ZoghbiDirector | Sold · 11 lines | 1,638 | $781.33 | $1.3M | Feb 19, 2026 | 4d |
| Arthur F. RyanDirector | Sold · 7 lines | 90 | $778.05 | $70K | Feb 9, 2026 | 2d |
| Jason PitofskySVP Controller | Sold · 11 lines | 2,036 | $778.52 | $1.6M | Feb 9, 2026 | 2d |
| Bonnie L. BasslerDirector | Sold | 1,500 | $800.00 | $1.2M | Jan 7, 2026 | 1d |
One row is one filing. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count.
Congress trades in REGN
20 disclosures of 174 on record · median 27d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +19.4%S&P +2.0% · vs S&P 500 +17.4% | Jul 7, 2026 | Aug 7, 2026 | 31d |
| Alan ArmstrongSelfFiled late | Stock | Purchase | $1,001 - $15,000 | +9.5%S&P +20.2% · vs S&P 500 -10.7% | Mar 27, 2026 | Jul 21, 2026 | 116d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +34.0%S&P +0.4% · vs S&P 500 +33.6% | Jun 2, 2026 | Jul 6, 2026 | 34d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +31.4%S&P +1.6% · vs S&P 500 +29.8% | Jun 16, 2026 | Jul 6, 2026 | 20d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +15.1%S&P +5.8% · vs S&P 500 +9.4% | May 1, 2026 | Jun 9, 2026 | 39d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +15.7%S&P +3.2% · vs S&P 500 +12.5% | May 15, 2026 | Jun 9, 2026 | 25d |
| Gilbert Ray Cisneros, Jr. | Stock | Sale | $1,001 - $15,000 | +15.7%S&P +3.2% · vs S&P 500 +12.5% | May 15, 2026 | Jun 8, 2026 | 24d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +8.2%S&P +11.1% · vs S&P 500 -2.9% | Apr 13, 2026 | May 11, 2026 | 28d |
| Julia Letlow | Stock | Purchase | $1,001 - $15,000 | +3.1%S&P +11.9% · vs S&P 500 -8.8% | Feb 12, 2026 | Mar 12, 2026 | 28d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +7.8%S&P +9.8% · vs S&P 500 -2.0% | Jan 29, 2026 | Feb 6, 2026 | 8d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +7.2%S&P +10.6% · vs S&P 500 -3.4% | Jan 23, 2026 | Feb 6, 2026 | 14d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | +11.4%S&P +15.5% · vs S&P 500 -4.1% | Nov 18, 2025 | Dec 15, 2025 | 27d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +25.8%S&P +11.6% · vs S&P 500 +14.2% | Nov 3, 2025 | Dec 8, 2025 | 35d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +44.0%S&P +14.9% · vs S&P 500 +29.2% | Sep 29, 2025 | Oct 3, 2025 | 4d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +37.4%S&P +18.2% · vs S&P 500 +19.3% | Aug 26, 2025 | Sep 9, 2025 | 14d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +41.8%S&P +21.4% · vs S&P 500 +20.4% | Aug 4, 2025 | Sep 9, 2025 | 36d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +43.4%S&P +19.7% · vs S&P 500 +23.7% | Jul 25, 2025 | Aug 7, 2025 | 13d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +51.0%S&P +23.4% · vs S&P 500 +27.6% | Jul 1, 2025 | Aug 7, 2025 | 37d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +35.4%S&P +28.2% · vs S&P 500 +7.2% | May 19, 2025 | Jun 10, 2025 | 22d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +36.5%S&P +29.7% · vs S&P 500 +6.7% | May 28, 2025 | Jun 10, 2025 | 13d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Members of Congress reporting a position
2 members · estimate, as of Sep 10, 20262 members report a position (estimated). The largest estimated position is in the $15,001 - $50,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Robert Bresnahan | Republican · House | $15,001 - $50,000 | 0.1% |
| Julia Letlow | Republican · House | $1,001 - $15,000 | 0.8% |
Estimate, as of Sep 10, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Awards, option exercises and gifts (16)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Kathryn GuariniDirector | Option exercise | 400 | Sep 2, 2026 |
| Joseph J. LarosaEVP General Counsel and Secret | Tax withholding | 9,019 | Aug 19, 2026 |
| Joseph J. LarosaEVP General Counsel and Secret | Option exercise | 12,282 | Aug 19, 2026 |
| Christopher R. FenimoreEVP Finance CFO | Tax withholding | 4,599 | Aug 18, 2026 |
| Christopher R. FenimoreEVP Finance CFO | Option exercise | 6,283 | Aug 18, 2026 |
| Kathryn GuariniDirector | Option exercise | 400 | Aug 10, 2026 |
| Huda Y. ZoghbiDirector | Option exercise | 800 | Aug 10, 2026 |
| Huda Y. ZoghbiDirector | Option exercise | 1,638 | Feb 19, 2026 |
| Jason PitofskySVP Controller | Option exercise | 1,000 | Feb 9, 2026 |
| Bonnie L. BasslerDirector | Option exercise | 1,500 | Jan 7, 2026 |
| Craig B. ThompsonDirector | Stock award | 2,117 | Jan 2, 2026 |
| Arthur F. RyanDirector | Stock award | 155 | Jan 2, 2026 |
| Huda Y. ZoghbiDirector | Stock award | 2,117 | Jan 2, 2026 |
| Kathryn GuariniDirector | Stock award | 2,117 | Jan 2, 2026 |
| David P. SchenkeinDirector | Stock award | 1,962 | Jan 2, 2026 |
| George L. SingDirector | Stock award | 155 | Jan 2, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Questions
Are insiders buying or selling REGN?
Across the 13 most recent open-market filings shown here, 0 were purchases and 13 were sales.
Which members of Congress have traded REGN?
Ro Khanna, Alan Armstrong, Gilbert Ray Cisneros, Jr., Julia Letlow disclosed REGN transactions in the filings shown here.
Which members of Congress hold REGN?
2 members of Congress report a position in REGN in the estimate we hold as of Sep 10, 2026. The two largest estimated positions belong to Robert Bresnahan and Julia Letlow. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
Is REGN in the S&P 500 or the Nasdaq 100?
Regeneron Pharmaceuticals, Inc. is a current member of the S&P 500 and Nasdaq 100, per the membership list we hold as of Sep 10, 2026. Current members of either index get a page here whatever their filing history.
How quickly are REGN trades disclosed?
Insider filings on this page reached the public a median of 2 days after the transaction, against the two business days Form 4 allows. Congressional disclosures took a median of 27 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.